Funding Opportunities
Learn more about D2R's newly launched funding programs.
D2R Funded Projects
D2R News & Stories
D2R Events
D2R | DNA to RNA
An inclusive Canadian approach to genomic-based RNA therapeutics
The time is now for discovery and development of genome-guided, RNA-based precision medicines for Canada and for the world. With a landmark $165 million investment from the Canada First Research Excellence Fund and additional support from the Quebec Government and philanthropic and industry partners, McGill’s world-leading research initiative DNA to RNA (D2R) will develop revolutionary genomic-based RNA medicines for all.
Discover the initiative
D2R's vision for Canada
Create groundbreaking medical treatments
D2R will improve health through rapid deployment of new lower cost medical treatments for previously “undruggable” pharmaceutical targets and untreated medical conditions.Tackle societal and policy issues
D2R will address unmet clinical needs of equity-deserving groups, including Canada’s Indigenous populations by engaging with patients, their families and patient organizations.Accelerate “next-generation” drug development
D2R will catalyze Canadian pharma/biotech to create a major international hub for “next-generation” drug development, industry partnerships and startups.
Our researchers & partners
McGill researchers have been uncovering the mechanisms and potential of RNA for over 50 years. From genomics and RNA biology to medicine and biomanufacturing, our research strengths cover the range of expertise needed to discover gene targets and develop new treatments for disease.
